A . 3.

SEQUENCE LISTING

```
<110> Lemaire, Simon
      Bernatchez-Lemaire, Irma
      Le, Hoang-Thanh
       Histogranin-like Peptides and Non-peptides, Processes
       for Their Preparation and Uses Thereof
       78490-7
<130>
<160>
       9
     PatentIn version 3.0
<170>
<210>
      1
<211> 15
<212> PRT
<213> Artificial
<220>
       Prior art peptide synthesized by solid-phase
<223>
       procedure
<400> 1
Met Asn Tyr Ala Leu Lys Gly Gln Gly Arg Thr Leu Tyr Gly Phe
                5
<210>
<211> 15
<212> PRT
<213> Artificial
<220>
       Prior art peptide synthesized by solid-phase
<223>
       procedure
<400> 2
Val Val Tyr Ala Leu Lys Arg Gln Gly Arg Thr Leu Tyr Gly Phe
                                                        15
<210>
      3
<211> 14
<212> PRT
<213> Artificial
<220>
       Prior art peptide synthesized by solid-phase
<223>
       procedure
<400> 3
Ala Leu Lys Arg Gln Gly Arg Thr Leu Tyr Gly Phe Gly Gly
```

Ball.

```
1
                5
                                     10
<210> 4
<211> 9
<212> PRT
<213> Artificial
<220>
       Prior art peptide synthesized by solid-phase
<223>
       procedure
<400>
       4
Gly Gln Gly Arg Thr Leu Tyr Gly Phe
<210>
       5
<211>
      PRT
<212>
      Artificial
<213>
<220>
<223> Cyclic tetrapeptide synthesized by solid-phase
       procedure
<220>
<221>
      Xaa
<222>
      (2)..(2)
<223> Xaa is p-Cl-Phe
<220>
<221>
       Xaa
       (4)..(4)
<222>
      Xaa is (D)-Arg
<223>
<400>
      5
Gly Xaa Tyr Xaa
<210>
       6
<211>
<212>
      PRT
       Artificial
<213>
<220>
<223>
      Cyclic tetrapeptide synthesized by solid-phase
       procedure
<220>
       Xaa
<221>
<222>
      (2)..(2)
<223>
       Xaa is p-Cl-Phe
```

2

and mar. 1-1/2/11/11/11/11/11

4 . R .

```
<220>
<221>
      Xaa
<222>
      (4)..(4)
<223> Xaa is p-amino-Phe
<400> 6
Gly Xaa Tyr Xaa
<210>
       7
<211>
      4
<212> PRT
<213> Artificial
<220>
      Cyclic tetrapeptide synthesized by solid-phase
<223>
       procedure
<220>
<221>
       Xaa
      (2)..(2)
<222>
      Xaa is p-Cl-Phe
<223>
<220>
<221>
       Xaa
       (4)..(4)
<222>
       Xaa is p-guanidino-Phe
<223>
<400> 7
Gly Xaa Tyr Xaa
<210>
       8
<211>
<212>
      PRT
<213> Artificial
<220>
<223> Cyclic tetrapeptide synthesized by solid-phase
       procedure
<220>
<221>
       Xaa
       (2)..(2)
<222>
```

3

Xaa is p-amino-Phe

<223>

<220>

```
<221>
       Xaa
<222>
      (4)..(4)
<223> Xaa is (D)-Arg
<400> 8
Gly Xaa Tyr Xaa
<210>
       9
<211>
       4
<212>
       PRT
      Artificial
<213>
<220>
       Cyclic tetrapeptide synthesized by solid-phase
<223>
       procedure
<220>
<221>
      Xaa
      (2)..(2)
<222>
<223> Xaa is p-Cl-Phe
<220>
<221>
      Xaa
      (4)..(4)
<222>
<223> Xaa is (D)-Arg
<400> 9
Thr Xaa Tyr Xaa
```

and committee the transfer of the second